JP2023533111A5 - - Google Patents

Info

Publication number
JP2023533111A5
JP2023533111A5 JP2022568780A JP2022568780A JP2023533111A5 JP 2023533111 A5 JP2023533111 A5 JP 2023533111A5 JP 2022568780 A JP2022568780 A JP 2022568780A JP 2022568780 A JP2022568780 A JP 2022568780A JP 2023533111 A5 JP2023533111 A5 JP 2023533111A5
Authority
JP
Japan
Prior art keywords
sting agonist
inhibitor
use according
ctla4
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533111A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/032800 external-priority patent/WO2021232019A1/en
Publication of JP2023533111A publication Critical patent/JP2023533111A/ja
Publication of JP2023533111A5 publication Critical patent/JP2023533111A5/ja
Pending legal-status Critical Current

Links

JP2022568780A 2020-05-15 2021-05-17 免疫チェックポイント阻害剤とのstingアゴニスト併用治療 Pending JP2023533111A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063025905P 2020-05-15 2020-05-15
US63/025,905 2020-05-15
US202063091874P 2020-10-14 2020-10-14
US63/091,874 2020-10-14
PCT/US2021/032800 WO2021232019A1 (en) 2020-05-15 2021-05-17 Sting agonist combination treatments with immune checkpoint inhibitors

Publications (2)

Publication Number Publication Date
JP2023533111A JP2023533111A (ja) 2023-08-02
JP2023533111A5 true JP2023533111A5 (cg-RX-API-DMAC10.html) 2024-05-24

Family

ID=76306053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568780A Pending JP2023533111A (ja) 2020-05-15 2021-05-17 免疫チェックポイント阻害剤とのstingアゴニスト併用治療

Country Status (10)

Country Link
US (1) US20210380695A1 (cg-RX-API-DMAC10.html)
EP (1) EP4149457A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023533111A (cg-RX-API-DMAC10.html)
KR (1) KR20230011324A (cg-RX-API-DMAC10.html)
CN (1) CN115803032A (cg-RX-API-DMAC10.html)
AU (1) AU2021273508A1 (cg-RX-API-DMAC10.html)
CA (1) CA3178464A1 (cg-RX-API-DMAC10.html)
IL (1) IL298148A (cg-RX-API-DMAC10.html)
MX (1) MX2022014110A (cg-RX-API-DMAC10.html)
WO (1) WO2021232019A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114940679B (zh) * 2022-05-23 2023-05-16 浙江大学医学院附属第四医院 Sting激动剂前药化合物及其制备方法和应用
WO2024064724A1 (en) * 2022-09-21 2024-03-28 The University Of North Carolina At Chapel Hill Compositions and methods for treating cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2935257T3 (es) 2013-03-15 2023-03-03 Univ Chicago Métodos y composiciones relacionadas con la actividad de las células T
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
CN103908468B (zh) 2014-04-21 2017-02-08 上海捌加壹医药科技有限公司 环二核苷酸cGAMP在制备抗肿瘤药物中的应用
DK3233882T3 (da) 2014-12-16 2020-01-27 Kayla Therapeutics Fluorinerede cykliske dinukleotider til cytokininduktion
EP4122492A1 (en) * 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
US20170158772A1 (en) 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
DE212016000029U1 (de) 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
IL280430B2 (en) * 2016-03-18 2023-11-01 Univ Texas Cyclic dinucleotide compounds and methods of use
RU2019122598A (ru) 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Циклические динуклеотидные агонисты sting для лечения рака
WO2018118664A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3675859A4 (en) 2017-08-31 2021-06-30 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
EP3755331B1 (en) 2018-02-21 2026-01-28 The Scripps Research Institute Agonists of stimulator of interferon genes (sting) for use in the treatment of cancer
JP2023500045A (ja) * 2019-10-14 2023-01-04 イミューンセンサー セラピューティクス、インコーポレイテッド Stingアゴニストを用いたがんを処置する方法

Similar Documents

Publication Publication Date Title
Theiss et al. Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis
Aglietta et al. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
Wang et al. Treatment of chronic subdural hematoma with atorvastatin combined with low-dose dexamethasone: phase II randomized proof-of-concept clinical trial
Goedegebuure et al. Combining radiotherapy with anti-angiogenic therapy and immunotherapy; a therapeutic triad for cancer?
Yamaguchi et al. Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab
McDermott et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon α-2B in patients with metastatic melanoma
Theiss et al. Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction
RU2011104955A (ru) Композиции антител
RU2017132877A (ru) Комбинация антагониста pd-1 и эрибулина для лечения рака
CA2993179A1 (en) Combination of immunomodulatory agent with pd-1-or pd-l1 checkpoint inhibitors in the treatment of cancer
Flowers et al. Efficacy of pharmacokinetics-directed busulfan, cyclophosphamide, and etoposide conditioning and autologous stem cell transplantation for lymphoma: comparison of a multicenter phase II study and CIBMTR outcomes
JP2019508433A5 (cg-RX-API-DMAC10.html)
JP2019218359A (ja) Gd2陽性がんを処置するための製剤および方法
Numico et al. Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence
JP2023539625A5 (cg-RX-API-DMAC10.html)
JP2019533715A5 (cg-RX-API-DMAC10.html)
CA3160502A1 (en) Formulations of anti-cd38 antibodies for subcutaneous administration
Puri et al. Effects of different doses of intraumbilical oxytocin on the third stage of labor
Song et al. Glutamine protects mice from acute graft-versus-host disease (aGVHD)
Schwartz et al. Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)–paclitaxel or docetaxel adjuvant chemotherapy in breast cancer
Lee et al. Pharmacological treatments for basal cell carcinoma
Zhao et al. Emerging immunological strategies: recent advances and future directions
IL320024A (en) Perk inhibitor hc-5404 in combination with anti-pd-1 antibody and/or an antiangiogenetic agent for use in the treatment of cancer
Pabón-Cartagena et al. Eosinophilic fasciitis in association with nivolumab: The importance of eosinophilia
Petitdemange et al. Immune checkpoint inhibitors-induced systemic capillary leak syndrome: a report of two cases